MaxCyte Competitors and Similar CompaniesClear all
MaxCyte's competitors and similar companies include Miltenyi Biotec, Thermo Fisher Scientific, Senda Biosciences and Twentyeight-Seven Therapeutics.
 MaxCyte MaxCyte (formerly known as Theramed) is a cell engineering company focused on providing platform technologies for cell-based research as well as cell therapeutic discovery, development, and commercialization. |  Miltenyi Biotec Miltenyi Biotec is a company that specializes in biomedical research and cell and gene therapy. |  Thermo Fisher Scientific Thermo Fisher Scientific is a company specializing in laboratory equipment, analytical instruments, reagents, consumables, and related technologies for scientific research and applied testing. |  Senda Biosciences Senda Biosciences (formerly known as Kintai Therapeutics) is a company developing a platform that deconstructs nature-provided codes for therapeutic purposes. |  Twentyeight-Seven Therapeutics Twentyeight-Seven Therapeutics is a biotechnology company focused on the modulation of non-coding RNA (ncRNA) function to treat cancer and other human diseases. | |
Founding Date | Founding Date 1998 | Founding Date 1989 | Founding Date 1956 | Founding Date 2017 | Founding Date 2016 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Private |
Tags | |||||
Locations | Locations Gaithersburg, US HQ Alderley Edge, GB | Locations Bergisch Gladbach, DE HQ Sydney, AU Shanghai, CN Paris, FR Bielefeld, DE Cologne, DE Göttingen, DE see more | Locations Waltham, US HQ Buenos Aires, AR Buenos Aires, AR Buenos Aires, AR Adelaide Airport, AU Brendale, AU Canberra, AU see more | Locations Cambridge, US HQ | Locations Watertown, US HQ |
Employees | Employees 65 | Employees 3,0341% increase | Employees 125,000 | Employees 16 | Employees 6 |
Valuation ($) | Valuation ($) 387.9 m | Valuation ($) N/A | Valuation ($) 209.2 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $33m (FY, 2025) | Revenue (est.) €671.5m (FY, 2023) | Revenue (est.) $44.6b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $6.2m (FY, 2025) | Cost of goods €132.2m (FY, 2023) | Cost of goods $26.3b (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $26.8m (FY, 2025) | Gross profit €539.4m (FY, 2023) | Gross profit $18.2b (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($44.6m) (FY, 2025) | Net income €11.4m (FY, 2023) | Net income $6.7b (FY, 2025) | Net income N/A | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 31.3m | Total funding raised N/A | Total funding raised $ 500m | Total funding raised N/A | Total funding raised $ 80m |
For sources of this data, please see the company profile
View Company Profiles
Miltenyi Biotec
HQ
Bergisch Gladbach, DE
Employees
3,034↑ 1% increase
Miltenyi Biotec is a company that specializes in biomedical research and cell and gene therapy.
View companyThermo Fisher Scientific
HQ
Waltham, US
Employees
125,000
Thermo Fisher Scientific is a company specializing in laboratory equipment, analytical instruments, reagents, consumables, and related technologies for scientific research and applied testing.
View companySenda Biosciences
HQ
Cambridge, US
Senda Biosciences (formerly known as Kintai Therapeutics) is a company developing a platform that deconstructs nature-provided codes for therapeutic purposes.
View companyTwentyeight-Seven Therapeutics
HQ
Watertown, US
Employees
6
Twentyeight-Seven Therapeutics is a biotechnology company focused on the modulation of non-coding RNA (ncRNA) function to treat cancer and other human diseases.
View company